NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Solo versus combo is post surgery/radiation. DCVVx-L trial used both prior to drug treatment: "Patients must enter screening at a participating site prior to surgical resection of the tumor. Patients will receive the standard of care, including radiation and Temodar therapy"

Dr, Liau then supplemented with PDL1 and ATL in the treatment arm. ATL was the comparator arm.

Just for context, here is the Novocure Optune Phase 3 results -- DCVax-L is not superior. "The five-year survival rate increased from five percent to 13 percent for patients treated with Optune together with temozolomide versus patients treated with temozolomide alone. These are the best results reported for newly diagnosed GBM patients in a phase 3 trial to date and represent a new landmark for five-year survival rate in this difficult to treat disease."